



# Biotech Daily

Monday July 7, 2025

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH DOWN: AMPLIA UP 20%; MEDADVISOR DOWN 11%**
- \* **NANOSONICS LAUNCHES TROPHON3, TROPHON2 PLUS**
- \* **MEDADVISOR SELLS \$35m AUSTRALIA, NZ BUSINESS TO JONAS**
- \* **MONASH \$25m MICRO-X MOBILE CT SCANNER PROJECT**
- \* **MONASH: 'OESTROGEN PROTECTS MOUSE HEARTS'**
- \* **BLUECHIIP ADMINISTRATORS SELL ASSETS; LIQUIDATION**
- \* **PYC PHASE Ia PYC-003 KIDNEY DISEASE TRIAL SAFE TO PROCEED**
- \* **ISLAND REQUESTS 'GALIDESIVIR PURCHASE' TRADING HALT**
- \* **MICROEQUITIES TAKES 9.5% OF MACH7**
- \* **MEDADVISOR TO LOSE CFO ANCILA DESAI**

## MARKET REPORT

The Australian stock market fell 0.16 percent on Monday July 7, 2025, with the ASX200 down 13.7 points to 8,589.3 points. Seven of the Biotech Daily Top 40 companies were up, 22 fell, eight traded unchanged and three were untraded.

Amplia was the best, on last week's news and for the second trading day in a row, up six cents or 20.3 percent to 35.5 cents, with 36.1 million shares traded. CSL, Immutep, Micro-X and Starpharma rose two percent or more; Curvebeam, Nanosonics and SDI climbed more than one percent; with Pro Medicus up by 0.7 percent.

Medadvisor led the falls for the second trading day in a row (see below), down 0.6 cents or 10.9 percent to 4.9 cents, with 7.5 million shares traded.

Botanix lost 8.8 percent; Paradigm and Proteomics were down more than seven percent; Clarity was down 6.5 percent; Actinogen, Cyclopharm, Medical Developments, Optiscan and Polynovo fell four percent or more; Dimerix, Imugene and Orthocell were down three percent or more; 4D Medical and EBR shed two percent or more; Avita, Emvision and Neuren were down more than one percent; with Aroa, Clinuvel, Cochlear, Mesoblast, Resmed and Telix down by less than one percent.

## NANOSONICS

Nanosonics says it has launched its Trophon3 third-generation ultra-sound probe decontamination device and Trophon2 Plus, software upgrade package.

In 2018, Nanosonics said it launched its Trophon2 second generation ultra-sound probe decontamination device in North America and Europe (BD: Aug 8, 2018).

Today, the company said it had begun commercializing its third-generation device and second-generation device software upgrades in Europe, the UK, Australia and New Zealand, and had filed regulatory submissions to the US Food and Drug Administration.

Nanosonics said Trophon3 was more than 40 percent faster than previous generations and delivered “a range of new customer benefits while maintaining the highest standard in clinical efficacy for patient safety”.

The company said Trophon3 had “expanded digital integration capabilities and offers the widest traceability capabilities in the ultra-sound reprocessing market including new digital traceability through customer’s [digital imaging and communications in medicine] imaging database systems, the international standard for medical imaging data”.

Nanosonics said Trophon3 was fully programable and could be “customized to suit a range of customer workflows enhancing efficiency while delivering consistent, reliable disinfection in a safe, effective, and environmentally friendly way”.

The company said Trophon3 was expected to strengthen its “leadership position, while supporting continued expansion of the installed base and driving the upgrade of customers from the first-generation Trophon EPR units to the latest platform”.

Nanosonics said it was launching its Trophon2 Plus “a new software upgrade package that makes all the key new Trophon3 features available to existing Trophon2 users”.

Nanosonics managing-director Michael Kavanagh said Trophon3 and Trophon2 Plus set a new benchmark in automated high-level disinfection for ultra-sound transducers, upholding the Trophon technology’s market leadership position”.

“These launches reflect our commitment to innovation, customer support and ongoing expansion in this important area of infection prevention”, Mr Kavanagh said.

Nanosonics was up six cents or 1.6 percent to \$3.91 with 955,990 shares traded.

## MEDADVISOR

Medadvisor says it has completed the \$35 million sale of its Australia and New Zealand business operations to Brisbane’s Jonas Software Aus Pty Ltd.

Last week, Medadvisor said it had a binding agreement to sell its Australia and New Zealand Business to the Toronto-based Constellation Software subsidiary Jonas Software for \$27 million up-front plus a three-year earn-out (BD: Jul 2, 2025).

Today, the company said Jonas had acquired 100 percent of the shares in its Australian operating entity, subsidiaries and UK investment in Charac, and that it would continue to operate its US business as Medadvisor Solutions under a royalty-free licence with Jonas.

Medadvisor said it had received the \$27 million up-front payment, with \$8 million held back and retained by Jonas, to be paid after normal transaction completion adjustments had been determined and settled.

The company said that it had repaid its \$US15.1 million (\$A23 million) finance facilities with Partners for Growth.

Medadvisor managing-director Rick Ratliff said the company was focussing on the US.

“While near-term market headwinds persist, we remain confident in the strength of our platform, the depth of our client relationships, and the strategic investments positioning us for long-term growth,” Mr Ratliff said.

Medadvisor fell 0.6 cents or 10.9 percent to 4.9 cents with 7.5 million shares traded.

## [MONASH UNIVERSITY](#)

Monash University says it will “lead the design of a first-of-its-kind mobile CT scanner” with Micro-X as part of a \$25 million development project.

Last year, Micro-X said it had won a \$US8.15 million (\$A12.75 million) grant from the US Advanced Research Projects Agency for Health to develop a portable full-body computed tomography (CT) scanner (BD: Dec 4, 2024).

Today, Monash University said that with Micro-X and Johns Hopkins University it had a contract for up-to \$25 million from the US Advanced Research Projects Agency to develop the light-weight CT scanners that could be fitted into mobile vehicles, providing hospital-level care regardless of location.

The University said the initiative would “address critical healthcare disparities in rural America, where many people face limited access to advanced medical imaging, resulting in delayed health diagnoses”.

Monash University said its Design Health Collab team would design the CT scanner, which would weigh just 225 kilograms, significantly lighter than conventional 2,000-kilogram CT scanners.

The University said the scanner’s reduced weight was made possible by Micro-X’s nano electronic x-ray technology, which used “miniaturized x-ray emitters to deliver high-quality, three-dimensional imaging comparable to hospital-based systems”.

Monash University said the technology aimed to provide “advanced medical imaging outside of hospitals, enabling quick and accurate detection of diseases in underserved areas”.

The University said with Micro-X and Johns Hopkins University it was one of 12 teams collaborating on various aspects of the US Advanced Research Projects Agency for Health’s Platform Accelerating Rural Access to Distributed and Integrated Medical Care program.

Monash University said the CT scanner was expected to be completed by 2029.

The University said its Design Health Collab team was “also looking to introduce similar design concepts locally to promote better access to healthcare and services in Australia”.

Micro-X chief executive officer Kingsley Hall said Micro-X’s miniaturized X-ray technology allowed the company to bring life-saving CT imaging to places it currently cannot go.

“Micro-X continues to push boundaries, challenging the constraints of legacy X-ray technology to deliver new and innovative solutions that meet the needs of customers, users and patients,” Mr Hall said.

Monash project lead Dr Nyein Chan Aung said the role of design had made the technology a reality.

“Medical technology has seen a wave of miniaturization, from portable ultrasound to wearable health monitors, but CT scanners remain the final frontier,” Dr Aung said.

“Through design, we are now driving this transformation, making full-body CT imaging truly mobile for the first time,” Dr Aung said.

Monash director of Design Health Collab Prof Daphne Flynn said the team was focused on design that extend distributed healthcare beyond hospital walls.

“Design Health Collab is committed to improving the experience and equity of healthcare, where communities can access services regardless of where they live,” Prof Flynn said.

“This project demonstrates Monash University’s place on the world stage in innovation and design, and we’re proud to be working with our partners to create more accessible health outcomes across the world,” Prof Flynn said.

Micro-X was up 0.1 cents or 2.2 percent to 4.6 cents.

## MONASH UNIVERSITY

Monash University says the female sex hormone oestrogen protects the heart of females with high blood pressure, in mice.

Monash University said it found that oestrogen increases the levels of a natural protein called annexin-A1 (ANXA1), in female mice, and that “the findings suggest that the oestrogen-ANXA1 association plays an important role in protecting women’s hearts from damage caused by high blood pressure”.

The University said the research, titled ‘Annexin-A1 deficiency uncovers female-specific pathways in blood pressure control and cardiovascular remodeling in mice’ was published in Communications Biology, with the full article available at:

<https://www.nature.com/articles/s42003-025-08291-6#Sec2>.

Senior author and head of molecular proteomics at the Baker Heart and Diabetes Institute Prof David Greening said the study showed “the power of proteomics, the large-scale study of proteins, in advancing our understanding of the causes of heart and blood vessel diseases”.

“It also provides detailed molecular insights into why men and women experience these conditions differently, helping us move toward more precise and targeted therapies for high blood pressure and related heart problems,” Prof Greening said.

Monash University said the research was “an important step toward developing heart disease treatments tailored specifically for women, addressing a gap that has been overlooked in medical research for a long time”.

The University said its researchers would advance the findings to clinical testing, particularly to benefit women with high blood pressure.

## BLUECHIIP

Bluechiip administrator Romanis Cant says the sale of the company’s assets has been finalized and a second meeting of creditors voted for the company to be wound up.

Romanis Cant said the sale of Bluechiip’s assets had “been finalized and based on the quantum of the purchase price for the company’s assets, there appears to be no real prospect of a dividend being paid to unsecured creditors ... [and] no return to shareholders”.

The administrators said the purchaser’s offer was solely for the acquisition of the company’s assets and did not allow for the recapitalization of the company via a deed of company arrangement.

Bluechiip had a market capitalization of about \$3.62 million.

Last year, the ASX said it had suspended Bluechiip under Listing Rule 17.5 for “not lodging the relevant period report by the due date” (BD: Oct 1, 2024).

Earlier this year, the company said it appointed Romanis Cant’s Manuel Hanna as its voluntary administrator and that he would undertake “an assessment of the company’s business operations and financial affairs” (BD: Mar 18, 2025).

At that time, the ASX separately said “having regard to the announcement of the appointment of voluntary administrators ... ASX has determined that Bluechiip’s financial condition is not adequate to warrant the continued quotation of its securities and therefore Bluechiip is in breach of Listing Rule 12.2”.

Last month, the administrators said a creditors meeting would vote on whether Bluechiip’s administration should end or whether the company should be wound up in the absence of receipt of a deed of company arrangement (BD: Jun 25, 2025).

Today, Romanis Cant’s Manuel Hanna was appointed liquidator.

Bluechiip last traded at 0.03 cents.

### PYC THERAPEUTICS

PYC says it has approval to dose the third cohort of healthy volunteers and first cohort of polycystic kidney disease patients in its phase Ia trial of PYC-003.

Earlier this year, PYC said it had approval to begin human trials of PYC-003 for polycystic kidney disease in a single ascending dose study, with a primary endpoint of safety, with data expected by 2026 (BD: Feb 10, 2025).

Later, the company said it had approval to proceed to the second, 1.2mg/kg dose cohort of the study (BD: May 26, 2025).

Today, PYC said the third volunteer cohort would be dosed with 2.4mg/kg of PYC-003, with the first cohort of polycystic kidney disease patients to receive 0.4mg/kg.

The company did not disclose the number of patients in the trial or each cohort.

PYC chief executive officer Dr Rohan Hockings said the dose administered in cohort two was “expected to be at the upper end of the efficacy range in humans based on the pre-clinical data”.

“Establishing safety/tolerability at a dose that we are happy to progress into pivotal studies is an important milestone,” Dr Hockings said.

PYC was up 17 cents or 13.3 percent to \$1.45.

### ISLAND PHARMACEUTICALS

Island has requested a trading halt “regarding the execution of an asset purchase agreement with Biocryst Pharmaceuticals Inc in relation to the galidesivir program”.

Last year, Island said it had paid Durham, North Carolina’s Biocryst \$US50,000 (\$A75,109) for a 12-month exclusive period in which it can acquire Biocryst’s galidesivir anti-viral molecule (BD: Jul 3, 2024).

Trading will resume on July 9, 2025, or on an earlier announcement.

Island last traded at 14.5 cents.

### MACH7 TECHNOLOGIES

Microequities Asset Management Pty Ltd says it has increased its substantial shareholding in Mach7 from 19,935,108 shares (8.26%) to 22,319,888 shares (9.50%).

The Melbourne-based Microequities said it bought 2,384,780 shares between February 4 and July 3, 2025 for \$861,869, or 36.1 cents a share.

Mach7 was up two cents or 6.1 percent to 35 cents.

### MEDADVISOR

Medadvisor says chief financial officer Ancila Desai will step down, expected October 3, 2025, following the sale of its Australia and New Zealand business (see above).

Medadvisor said it intended to appoint a chief financial officer for Medadvisor Limited based in Australia and the process was well advanced, with an appointment expected shortly.